213: How the Fed affects biotech, Paul Offit on vaccines for kids, & another Alzheimer's setback

Will biotech stocks ever recover? How well do Covid-19 vaccines work for kids? And can anything stop the amyloid hypothesis? Longtime biotech investor Les Funtleyder joins us to explain why the recent interest rate hike is bad for biotech and just what it will take for the industry to get out of its slump. Then, vaccinologist and FDA adviser Paul Offit calls in to talk about the impending authorization of Covid-19 vaccines for young children and what it means for the future of the pandemic. We also explain the latest disappointing clinical trial in Alzheimer's disease and some perplexing data on Pfizer's Covid-19 antiviral.